Liposomes as novel anti-infectives targeting bacterial virulence factors?

Expert Review of Anti-Infective Therapy

Volumn 13, Issue 5, 2015, Pages 531-533

  Da Silveira, Samareh Azeredo ^a   Perez, Antonio ^a  

^a Lascco SA   (Switzerland)

Author keywords

Virulence

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL TOXIN; CAL 02; LIPOSOME; MEDI 4893; NANOPARTICLE; PORE FORMING CYTOTOXIC PROTEIN; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; LIPID BILAYER; NONHUMAN; REVIEW; BACTERIAL INFECTIONS; CHEMISTRY; GENETIC ENGINEERING;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; GENETIC ENGINEERING; HUMANS; LIPOSOMES; PORE FORMING CYTOTOXIC PROTEINS; VIRULENCE FACTORS;

EID: 84927674621     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2015.1028367     Document Type: Review

References (17)

1. Ling LL, Schneider T, Peoples AJ, et al. A new antibiotic kills pathogens without detectable resistance. Nature 2015;517: 455-9
2. Toussaint KA, Gallagher JC. b-Lactam/b-lactamase inhibitor combinations: from then to now. Ann Pharmacother 2015;49:86-98
3. Allen RC, Popat R, Diggle SP, Brown SP. Targeting virulence: can we make evolution-proof drugs? Nat Rev Microbiol 2014;12:300-8
4. Cegelski L, Marshall GR, Eldridge GR, Hultgren SJ. The biology and future prospects of antivirulence therapies. Nat Rev Microbiol 2008;6:17-27
5. Rasko DA, Sperandio V. Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov 2010;9: 117-28
6. Los FC, Randis TM, Aroian RV, Ratner AJ. Role of pore-forming toxins in bacterial infectious diseases. Microbiol Mol Biol Rev 2013;77:173-207
7. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997;387:569-72
8. Henry BD, Neill DR, Becker KA, et al. Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice. Nat Biotechnol 2015; 33(1):81-8
9. Hirst RA, Kadioglu A, O'Callaghan C, Andrew PW. The role of pneumolysin in pneumococcal pneumonia and meningitis. Clin Exp Immunol 2004;138:195-201
10. Lucas R, Czikora I, Sridhar S, et al. Mini-review: novel therapeutic strategies to blunt actions of pneumolysin in the lungs. Toxins (Basel) 2013;5:1244-60
11. Anderson R, Steel HC, Cockeran R, et al. Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro. J Antimicrob Chemother 2007;60:1155-8
12. Kaur R, Surendran N, Ochs M, Pichichero ME. Human antibodies to PhtD, PcpA, and Ply reduce adherence to human lung epithelial cells and murine nasopharyngeal colonization by Streptococcus pneumoniae. Infect Immun 2014;82:5069-75
13. Prymula R, Pazdiora P, Traskine M, et al. Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers a phase II randomized clinical trial. Vaccine 2014;32:3025-34
14. Leroux-Roels G, Maes C, De Boever F, et al. Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: a phase I/II randomized clinical study. Vaccine 2014;32: 6838-46
15. Mann B, Thornton J, Heath R, et al. Broadly protective protein-based pneumococcal vaccine composed of pneumolysin toxoid-CbpA peptide recombinant fusion protein. J Infect Dis 2014;209:1116-25
16. Bitounis D, Fanciullino R, Iliadis A, Ciccolini J. Optimizing druggability through liposomal formulations: new approaches to an old concept. ISRN Pharm 2012;2012:738432
17. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56: 600-12